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(57] ABSTRACT 
This invention relates to a novel class of heterocyclic 
compounds useful for selectively inhibiting elastase, 
selectively inhibiting chymotrypsin-like enzymes, selec-
tively inhibiting trypsin-like enzymes, or for generally 
inhibiting serine proteases of all classes. 
5 Claims, No Drawings 
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2 
HETEROCYCLIC INHIBITORS OF SERINE 
PROTEASES 
RELATED APPLICATIONS 
valuable peptides and proteins. Such proteolysis often 
destroys or alters the activity and/or function of the 
peptides and proteins. Uses would include the addition 
of the inhibitors to antibodies, enzymes, plasma prote-
5 ins, tissue extracts, or other proteins which are widely 
sold for use in clinical analysis, biomedical research, and 
for many other reasons. For some uses a specific inhibi-
tors would be desirable, while in other cases, an inhibi-
tor with general specificity would be preferred. 
10 
DETAILED DESCRIPTION OF THE 
INVENTION 
This application is a divisional of Ser. No. 
07/499,561, filed on Mar. 26; 1990, now U.S. Pat. No. 
5,109,018, issued on Apr. 28, 1992, which in tum is a 
file-wrapper continuation of Ser. No. 07/215,994, filed 
on Jul. 7, 1988, now abandoned, which in tum is a con-
tinuation of Ser. No. 06/874,459, filed on Jun. 13, 1986, 
now abandoned, which in turn is a continuation of Ser. 
No. 06/642,995, filed on Aug. 20, 1984, now U.S. Pat. 
No. 4,596,822, issued on Jun. 24, 1986. 
BACKGROUND OF THE INVENTION 
Certain substituted isocoumarins have been found to 
be excellent inhibitors of a number of serine proteases 
15 including human leukocyte elastase, porcine pancreatic 
elastase, bovine chymotrypsin, human cathepsin G, 
This invention relates to a novel class of heterocyclic various human and bovine blood coagulation enzymes, 
· compounds useful for selectively inhibiting elastase, human complement factor D, and several mammalian 
selectivelyinhibiting chymotrypsin-like enzymes, selec- mast cell proteases. These compounds inhibit the serine 
tively inhibiting trypsin-like enzymes, or for generally 20 proteases by acylating the active site serine residue and 
inhibiting serine proteases of all classes. Certain clinical in some cases form an additional covalent bond. These 
symptoms found in pancreatitis, emphysema, rheuma- structures may be used in vivo to treat diseases resulting 
toid arthritis, inflammation, and adult respiratory dis- from tissue destruction due to elastase, chymotrypsin, 
tress syndrome are beHeved to be caused by uncon- _trypsin, and related enzymes. They may be used in vitro 
trolled elastase in the affected tissues. Likewise, similar 25 to prevent proteolysis that occurs during the produc-
clinical symptoms found in the. same diseases are be- tion, isolation, purification, storage, and transport of 
lieved to be caused by uncontrolled cathepsin G, mast peptides and proteins. The novel substituted isocouma-
cell chymase, and other chymotrypsin-like enzymes. In rins and related heterocyclic analogs have the following 
vitro, proteolysis by serine proteases of the elastase, structural formula: 
chymotrypsin, and trypsin families is often a severe 30 
problem in the production, isolation, purification, trans-
port and storage of valuable peptides and proteins. 
It is an object of this invention to find a novel group 
of specific inhibitors for elastase, chymotrypsin, trypsin, 
and other serine proteases of similar substrate specific- 35 
ity, and serine proteases in general. Inhibitors are sub-
stances which reduce or eliminate the catalytic activity 
of enzymes. Chymotrypsin and chymotrypsin-like en-
zymes normally cleave peptide bonds in proteins and 
peptides where the amino acid residue on the carbonyl 40 
side of the split bond (P1 residue) is typically Trp, Tyr, 
Phe, Met, Leu or other amino acid residues which con-
tain. aromatic or large alkyl side chains. Elastase and 
elastase-like enzymes, on the other hand, cleave peptide 
bonds where the P1 amino acid residue is much smaller, 45 
typically Ala, Val, Ser, Leu and other similar amino 
acids. Trypsin-like enzymes hydrolyze peptide bonds 
where the P1 amino acid is Lys or Arg. All of the above 
enzymes have extensive secondary specificity and rec-
ognize amino acid residues removed from the P1 resi- 50 
due. The inhibitors of this invention would be useful for 
treating diseases such as pancreatitis, emphysema, rheu-
matoid arthritis, adult respiratory distress syndrome, 
and inflammatory diseases which involve destruction of 
tissue by serine proteases. In some cases, it would be 55 
more useful to utilize a specific elastase, trypsin or 
chymotrypsin-like enzyme inhibitor, while in other 
cases an inhibitor with broader specificity would be 
appropriate. 
It is an object of this invention to find a novel group 60 
of specific inhibitors useful in vitro for inhibiting elas-
tase, trypsin, chymotrypsin and other serine proteases 
of similar specificity, and for inhibiting serine proteases 
in general. Such inhibitors could be used to identify new 
proteolytic enzymes encountered in research. They 65 
could also be used in research and industrially to pre-
vent undesired proteolysis that occurs during the pro-
duction, isolation, purification, transport and storage of 
0 Rwll I x 
~ #z 
y 
wherein 
X is selected from the group consisting of 0 and S, 
Z is selected from the group consisting of H, halogen, 
C1-6alkyl, C1-6alkyl with an attached phenyl, Ct-6 
. fluorinated alkyl, C1-6 alkoxy, C1-6 fluorinated 
alkoxy, Ct-6 alkoxy with an attached phenyl, ben-
zyloxy, 4-fluorobenzyloxy, -OCH2C6H4-R' (2-
substituent), -OCH2C6H4-R' (3-substituent), 
-OCH2C6H4-R' (4-substituent) -OCH2C6-
H3-R2' (2,3-substituents) -OCH2C6H3-R2' (2,4-
substituents), -OCH2C6H3-R2' (2,5-substitu-
ents), -OCH2C6HJ-R2' (2,6-substituents), 
-OCH2C6H3-R2' (3,4-substituents), -OCH2C6-
H3-R2' (3,5-substituents), 
R' is selected from the group consisting of H, halo-
gen, trifluoromethyl, N02, cyano, methyl, me-
thoxy, acetyl, carboxyl, OH, and amino, 
Y is selected from the group consisting ofH, halogen, 
trifluoromethyl, methyl, OH, and methoxy, 
R is selected from the group consisting of H, OH, 
NH2, N02, halogen, -NH-C(NH)-NH2, 
-C(NH)NH2, C1-6 alkoxy, C1-6 fluorinated alk-
oxy, C1-6 alkyl, Ct-6 alkylamino, M-AA and 
M-NH, 
wherein AA is selected from the group consisting 
of alanine, valine, leucine, isoleucine, praline, 
methionine, phenylalanine, tryptophan, glycine, 
serine, theronine, cysteine, tyrosine, asparagine, 
glutamine, aspartic acid, glutamic acid, lysine, 
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arginine, histidine, beta-alanine, norleucine, nor-
valine, alpha-aminobutyric acid, epsilon-
aminocaproic acid, citrulline, hydroxyproline, 
ornithine, and sarcosine, 
wherein M is selected from the group consisting of 5 
hydrogen, lower alkanoyl having 1 to 6 carbons, 
carboxylalkanoyl, hydroxyalkanoyl, amino-
alkanoyl, benzene sulfonyl, tosyl, benzoyl, and 
lower alkyl sulfonyl having 1 to 6 carbons. 
Several of these compounds have been prepared ear- 10 
lier for other purposes (illustrative examples: Davies 
and Poole, J. Chem. Soc., pp 1616-1629 (1928); Milev-
skaya, Belin.skaya, and Yagupol'skii, Zhur. Org. Khim. 
9, pp 2145-2149, (1973); Tirodkar and Usgaonkar, Ind. 
J. Chem. 7, pp 1114-ll 16, (1969); Choksey and Usgaon- 15 
kar, Ind. J. Chem. 148, pp. 596-598, (1976)). 
The following compounds are representative of the 
invention: 
3-chloroisocoumarin, 20 
TABLE I-continued 
lnactiviation of Proteases by 3,4-Dichloroisocoumarin°. 
Enzyme 
Rat Mast Cell Protease Ilb 
Human Skin Chymase 
Bovine Chymotrypsin·A 
S. griseus Protease A 
Subtilisin 
Human Thrombin< 
Bovine Thrombin 
Human Plasmin 
Porcine Pancreatic Kallikrien< 
Bovine Factor Xa< 
Bovine Factor Xia< 
Human Factor Xlla< 
Human Factor D 
Bovine Trypsin 
S. aureus Protease V-8' 
Acetylcholincsterasef 
Beta-Lactamasof 
Papainh 
Leucine aminopeptidase' 
Inhibitor 
Concen-
!ration 
(M) 
11.0 
92.0 
13.0 
136.0 
340.0 
127.0 
203.0 
127.0 
422.0 
239.0 
135.0 
109.0 
127.0 
18.0 
157.0 
385.0 
422.0 
400.0 
tj kobsdl[I] 
(min) (M-Is-1) 
1.8 583 
4.7 27 
1.6 566 
0.3 306 
substrate 
3.4 10 
3.7 25 
0.4 133 
3.4 27 
133.0 0.2 
1.8 27 
1.3 64 
0.6 192 
0.5 198 
0.3 2765 
>120 <0.6 
Nlg 
NI 
NI 
3,4-dichloroisocoumarin, 
3-ethoxy-4-chloroisocoumarin, 
3-isobutyloxy-4-chloroisocoumarin, 
3-benzyloxy-4-chloroisocoumarin, 
3-(4-fluorobenzyloxy)-4-chloroisocoumarin, 
7-amino-3-methoxy-4-chloroisocoumarin, 
7-amino-3-ethoxy-4-chloroisocoumarin, 
7-amino-3-benzyloxy-4-chloroisocoumarin, 
7-nitro-3-methoxy-4-chloroisocoumarin, 
7-nitro-3-ethoxy-4-chloroisocoumarin, 
7-nitro-3-benzy loxy-4-chloroisocoumarin, 
7-hydroxy-3-ethoxy-4-chloroisocoumarin, 
7-nitro-3-methoxyisocoumarin, 
0Jnactivation measurements were pcrfonncd using the incubation method in 0.1 M 
Hepes, 0.5 M NaCl, 8-10% Me2SO, pH 7.5 using the incubation method. An aliquot 
of inhibitor was added to an enzyme solution and aliquots removed with time and 
25 assayed for remaining enzymatic activity. First order rate constants, Kobrdi were 
obtained from the slope of plots of In (v/v0) versus times. 
1Pata obtained by progress curve method of Tian and Tsou, Biochemistry 21, 
1028-1032, (1982). 
"Incubation and assay buffer was 0.1 M Hepes, S mM CaCl2, 8-10% Me2SO, pH 7.5. 
doata obtained using the progress curve method (0.1 M Hepes, 5 mM CaCl2. 10% 
Me2SO, pH 7.5. 
30 'Buffer was 0.1 M Hepes, 109' Me2SO, pH 7.5. 
!Buffer was 0.1 M phosphate, 10% Me2SO, pH 7.0. 
SNl, no inactivation. 
7-nitro-3-(2-phenethoxy )-4-chloroisocoumarin, 
7-amino-3-(2-phenethoxy )-4-chloroisocoumarin, and 
7-(N-tosyl-phenylalany !amino )-4-chloro-3-methox-
yisocoumarin. 
When R is H, NH2, N02, X is 0, and Y and Z are any 
35 
of the noted groups, the isocoumarin structure is a gen-
eral inhibitor for both human leukocyte (HL) elastase 40 
and bovine chymotrypsin. Although these substituted 
isocoumarins are slightly less effective toward porcine 
pancreatic (PP) elastase and cathepsin G, they are still 
capable of inhibiting these enzymes. The rate constants 
for inactivation of HL elastase, PP elastase, and chymo- 45 
trypsin by 3-chloroisocoumarin (X=O, Z=CI, and 
Y = H) have been measured and are published, (Harper, 
Hemmi, and Powers, J. Amer. Chem. Soc. 105, pp 
6518-6520 (1983)). This publication is incorporated 
herein by reference. The 3-chloroisocoumarin also inac- 50 
tivates rat mast cell proteases I and II and Streotomyces 
oriseus protease A with rates of 84, 85, and 196 M-1 
s-1, respectively. Rate constants for inactivation of a 
number of elastase, chymotrypsin, and trypsin-like en-
zymes by 3,4-dichloroisocoumarin (R=H, X=O, 55 
Y =Z=CI) are given in Table I. This table indicates the 
generality of this compound as a serine protease inhibi-
tor. 
"Buffer was 0.05 M Tris HCI, 5 mM cysteine, 2 mM ethylenediaminetetrucetic acid, 
109' Me2SO, pH 8.2. 
Table II shows the inactivation rate constants for 
several serine proteases inhibited by substituted 3-alkox-
yisocoumarins. These Kobsdi[I] values are second order 
inactivation rate constants and reflect irreversible inac-
tivation of the enzyme. In some cases (see Tables I and 
II), inactivation rate constants were measured in the 
presence of substrate using the progress curve method 
as described by Tian and Tsou, Biochemistry 21, pp 
1028-1032, (1982). Signitic::ant, and in most cases total, 
inactivation of the enzyme will occur if the inhibitor 
concentration is chosen to be 5 to 50 times the enzyme 
concentration. The 7-amino-4-chloro-3-methox-
yisocoumarin is an essentially stoichiometric inactivator 
of PP elastase and chymotrypsin. 
The rate at which the enzyme is inactivated can be 
altered by changing both R, Z, and Y. The structures 
with long alkoxy or benzyloxy substituents are best at 
inhibiting chymotrypsin, while the most effective HL 
elastase inhibitors contain Z groups of Cl and Cl-4 
alkyloxy. Isocoumarin itself (X=O, Z= Y =H, and 
R=H) does not inhibit serine proteases. One of the most 
effective inhibitors of the blood coagulation proteases 
and other trypsin-like enzymes was 3,4-
dichloroisocoumarin (Z=Y=CI, R=H, X=O). At-
T ABLE 1 tachment of positively charged groups such as guani-
--------------------- 60 dine or amines in R or Z would make the inhibitor 
lnactiviation of Proteases by 3.4-Dichloroisocoumarin°. 
Enzyme 
Human Leukocyte Elastaseb 
Porcine Pancreatic Elastase 
Human Leukocyte Cathespin G 
Rat Mast Cell Protease I 
Inhibitor 
Concen-
!ration 
(M) 
I.I 
8.1 
49.0 
38.0 
t1 kabsdl[I] 
(min) (M- 1s- 1) 
1.2 8920 
0.57 2500 
8.4 28 
1.2 259 
65 
reactive towards trypsin-like enzymes. Additional spec-
ificity towards a particular protease could be achieved 
by the placing the proper aminoacid or peptide deriva-
tive on the 7-amino group. Thus the specificity or gen-
erality of the inhibition reaction can be controlled first, 
by choosing the appropriate inhibitor structure and 
second, by choosing the inhibitor concentration uti-
lized. 
5 
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TABLE II 
Rate Constrants (k9bsdl'[I]) for Inactivation of Serine Proteases by Substituted-4-chloroisocoumarins•. 
Enzl:'.!!!e 
Inhibitor HLEb PPF Cat Gd ChyT' RMCPIV SGPAK 
3-ethoxy+chloroisocoumarin 43oooh 940 190 610 3050 820 
3-isobutyloxy-4-chloroisocoumarin 9500 NV 190 750 920 6400 
3-benzyloxy+chloroisocoumarin 1525 6 1140 16000k 9600 5500 
3-(4-fluorobenzyloxy+chloroisocoumarin 2300 NI 216 320001 3200 3350 
7-nitro-3-methoxy+chloroisocoumarin 2580 580 
7-nitro-3-ethoxy-4-chloroisocoumarin 2800 1300 NI 4300 7000 2700 
7-nitro-3-benzyloxy+chloroisocoumarin 2600 10500 10500 
7-amino-3-mcthoxy+chloroisocoumarin 14000 1035 17 108 130 40 
7-amino-3-ethoxy+chloroisocoumarin 9420 700 195 274 876 216 
7-(Tos-Phe-NH) 4-chloro-3-methoxy isocoumarin 190000 6480 195 274 NI NI 
"()onditions were 0.1 M Hepes. O.S M NaCl, pH 7.S, 10% Me2SO, at 25' C .. Rate constants were obtained by the incubation method unless 
otherwise noted. An aliquot of inhibitor was added to a solution of enzyme and aliquots removed with time and assayed for remaining 
enzymatic activity. The fant order rate constants, Kab..f, were obtained from plots of In (v/v0) versus times. The units of K00,.i/[I] are 
M-ls-1. 
"inhibitor concentrations were from 0.007 to O.ot I mM. 
'Inhibitor concentrations were from 0.037 to 0.011 mM. 
~nhibitor concentrations were from 0. t 13 to 0.009 mM. 
'Inhibitor concentrations were from 0.013 to 0.098 mM . 
.!inhibitor concentrations were from 0.030 to 0.009 mM. 
'Inhibitor concentrations were from 0.086 to 0.005 mM. 
AProgress curve method with [I] = 175-600 nM. 
'Progress curve method with [I] = 0.012 mM. 
iNI, no inactivation. 
•Progress curve method with [I] = 0.0003-0.0017 mM. 
1Progress curve method with [I] = 0.0012 mM. 
The spontaneous hydrolysis rates of many of these 
substituted isocoumarins in buffer solution have mea-
sured and are summarized in Table III. The hydrolysis 
rates are dependent upon the composition of the buffer. 
In general, these isocoumarins are more stable in phos- 30 
phate buffered saline (pH 7.4) than in Hepes buffer (pH 
7.5). The most stable inhibitor studied was 7-amino-3-
methoxy-4-chloroisocoumarin while the most unstable 
was 3,4-dichloroisocoumarin. In addition, 7-amino-3-
methoxy-4-chloroisocoumarin is quite stable in albumin 35 
(0.4 mg/ml) while 3,4-dichloroisocoumarin decom-
posed rapidly upon addition to albumin (0.4 mg/ml). 
The 3-alkoxy-4-chloroisocoumarins are intermediate in 
stability. These compounds are significantly more stable 
than other serine protease inhibitors such as aza-pep- 40 
tides and sulfonyl fluorides. 
TABLE III 
Half-lives for Spontaneous Hydrolysis of 
Substituted Isocoumarins in Buffer Solution•. 
t1(min) 
Compound 
3-chloroisocoumarin 
3,4-dichloroisocoumarin 
3-ethoxy-4-chloro· 
isocoumarin 
3-benzyloxy-4-chloro· 
isocoumarin 
3-(4-fluorobenzyloxy)· 
4-chloroisocoumarin 
7-amino-3-methoxy 
4-chloroisocoumarin 
Hepe• 
pH 7.5b 
140 
18 
144 
68 
53 
195 
Phosphate 
pH 7.4< 
360 
48 
820 
0Spontaneous hydrolysis rates were measured spectrophotometrically by monitor· 
ing the decrease in absorbance due to the isocoumarin ring system (wavelength 
range: 385-325 nm) and these rates converted to half-lives using the first order rate 
law. 
45 
50 
55 
Chem. Soc., pp 402-410 (1963). The heterocyclic serine 
protease inhibitors of this invention have the following 
structural formula: 
wherein 
Rj•is selected from the group consisting of H, halo-
gen, C1-6alkyl, C1-6alkyl with an attached phenyl, 
C1-6 fluorinated alkyl, C1-6 alkoxy, C1-6fluorinated 
alkoxy, C1-6 alkoxy with an attached phenyl, ben-
zyloxy, 4-fluorobenzyloxy, -OCH2C6H4R' (2-
. substituent), -OCH2C6H4-R' (3-substituent), 
-OCH2C6H4-R' (4-substituent), -OCH2C6. 
H3-R2+ (2,3-substituents), -OCH2C6H3-R2' 
(2,4-substituents), -OCH2C6H3-R2' (2,5-substitu-
ents), -OCH2C6H3-R2' (2,6-substituents), 
-OCH2C6H3-R2 (3,4-substituents), and 
-OCH2C6H3-R2' (3,5-substituents), 
R' is selected from the group consisting of H, halo-
gen, trifluoromethyl, N02, cyano, methyl, me-
thoxy, acetyl, carboxyl, OH, and amino, 
R2 is selected from the group consisting of H, OH, 
NH2, N02, halogen, -NH-C(NH)-NH2, 
-C(NH)NH2, C1-6 alkoxy, C1-6 fluroinated alk-
oxy, C1-6 alkyl, and C1-6 alkylamino. 
The following novel compounds are representative 
of this invention: bConditions were: 0.1 Hepes buffer, 0.5 M NaCl, 10% Me2SO at 25' C., 
'Conditions were: 0.02 M KiHP04, 0.15 M NaCl. 10% Me2SO at 25' C .. 60 (1 H)2-benzopyran- l ,4(3H)-dione, 
It has been found that certain heterocyclic com· 
pounds will inhibit serine proteases such as elastase and 
chymotrypsin by blocking the active site of the enzyme. 
The compounds of this invention are 3-substituted-7- 65 
substituted-(1H)2-benzopyran-l,4(3H)-diones. The un-
substituted (1H)2-benzopyran-l,4(3H)-dione has been 
prepared previously for other purposes (cf. Knott, J. 
3-ethyl-( 1 H)2-benzopyran- l,4(3H)-dione, 
3-propyl-( 1 H)2-benzopyran- l ,4(3H)-dione, 
3-phenyl-( 1H)2-benzopyran- l ,4(3H)-dione. 
These structures inhibit serine proteases by forming 
relatively stable acyl enzymes. HL elastase (0.0004 mM) 
is totally inactivated by 3-propyl-1H-2-benzopyran-
l,4(3H)-dione (0.143 mM) while chymotrypsin (0.002 
mM) is totally inhibited by this compound at a concen-
5,281,721 
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tration of0.2 mM. The unsubstituted 1H-2-benzopyran-
l,4(3H)-dione is a less effective inhibitor than the propyl 
derivative towards HL elastase and chymotrypsin. · 
These compounds are more potent inhibitors of HL 
elastasc and chymotrypsin than cathepsin G and PP 5 
elastase. As with the substituted isocoumarins men-
tioned earlier,-the specificity of these structures towards 
a particular serine protease can be partially controlled 
by the nature of the substituent groups (Rt and R2). 
In the compounds of the present invention, the R 10 
group is critical for effective inhibition, and, no com-
1>9unds currently are known in the art with one of the 
listed R groups. There also are no compounds currently 
known in the literature or the prior art that are remotely 
related to the compounds claimed in the present inven- 15 
tion. The few known compounds have R=H, which is 
not claimed in the present invention. 
To use the above identified inhibitors in vitro, they 
are dissolved in an organic solvent such as dimethylsulf-
oxide or ethanol and are added to an aqueous solution 20 
containing the protease which is to be inhibited such 
that the final concentration of organic solvent is 25% or 
less. The inhibitors may also be added as solids or in 
suspension. 
The serine protease inhibitors of this invention wo.uld .25 
be useful in a variety of experimental procedures where· 
proteolysis is a significant problem. Inclusion of these 
inhibitors in radioimmunoasssay experiments would 
result in higher sensitivity. The use of these inhibitors in 
plasma fractionation procedures would result in higher 30 
yields of valuable plasma proteins and would make 
purification of the proteins easier. The inhibitors dis-
closed here could be used in cloning experiments utiliz-
ing bacterial cultures, yeast and E. coli and would result 
in a more easily purified cloned product in higher yie1d. 35 
It is well known in the literature that in vitro activity 
of elastase inhibitors correlates with in vivo activity in 
animal models of emphysema. Thus the novel inhibitors 
described here should be useful for the treatment of 
emphysema. Elastase inhibitors have been used orally, 40 by injection or by instillation in the lungs in animal 
studies (cf. Powers, Am. Rev. Respir. Dis., 127. s54-s58 
(1983) and references cited therein). The inhibitors de-
8 
portions. of ethyl acetate (50 mL). The aqueous layer 
was acidified to pH 2 with concentrated HCl and al-
lowed to stand overnight. The precipitate was filtered 
and dried to give benzyl 2-carboxyphenyl acetate (300 
mg) as a white solid: Rp0.7 (chloroform/methanol 
(9/1)). The benzyl 2-carboxyphenyl acetate (300 mg) 
was dissolved in benzene 7 mL) and PCls (474 mg, 2.28 
mmoles) added. The reaction mixture was refluxed for 
45 min and the benzene and POCIJ removed by rotary 
evaporation. Approximately one-half of the residue was 
chromatographed on silica gel using benzene as the 
eluent to give 3-benzyloxy-4-chloroisocoumarin (125 
mg) as a pale yellow solid: mp 92 deg centigrade, 
Rp0.63 (benzene). Anal. Calcd. for C16H1103Cl: C, 
67.02; H, 3.48. Found: C, 66.83; H, 3.86. 
EXAMPLE2 
Preparation of 
3-( 4-Fluorobenzyloxy )-4-Chloroisocoumarin 
Homophthalic acid (4.0 g) was added to a solution 
containing 4-fluorobenzyl alcohol (10 mL), benzene (10 
mL) and H2S04(3 drops) and the mixture refluxed at 80 
degrees centigrade for 2 h. The reaction mixture was 
diluted with ethyl acetate (125 mL) and washed with 
4% NaHC03 (500 mL). The aqueous layer was acidified 
to pH 3 with concentrated HCl and the solution placed 
in the refrigerator overnight. The crystals which 
formed upon cooling with filtered, dissolved in methy-
lene chloride, and dried over magnesium sulfate. The 
(4-fluorobenzyl) 2-carboxyphenyl acetate was collected 
from methylene chloride as a white solid (800 mg) and 
was used without further purification. The (4-fluoro-
benzyl) 2-caroxyphenyl acetate (0.8 g) was added 
slowly to a solution of PCls (l.16 g) in benzene (10 mL) 
and the mixture refluxed at 80 degrees centigrade for 45 
min. The benzene was removed, and the residue dis-
solved in diethyl ether, and filtered. The filtrate was 
concentrated and collected with isopropyl ether as pale 
yellow needles (500 mg): mp 127, IR (CH2C!i) 1743 
cm-1. Anal. Calcd. for C16H10CIF03 C, 63.07; H, 3.31. 
Found: C, 62.82; H, 3.36. 
scribed· above can be used by any of these routes. The EXAMPLE 3 
article by Powers (Am. Rev. Respir. Dis., 127, s54-s58 45 Preparation of 3-Isobutyloxy-4-Chloroisocoumarin (1983)) is incorporated herein by reference. 
Several other diseases also involve tissue destruction Homophthalic acid (4.0 g) was placed in isobutanol 
by proteases such as elastase-like and chymotrypsin-like (25 mL) and 3 drops of H2S04 added. The reaction 
enzymes (cf. Powers, Ad. in Chem., 198, 347-367 mixture was heated for 1 h at 100-110 degrees centi-
(1982)). This article by Powers is incorporated herein 50 grade, poured into 120 mL of ethyl acetate, and washed by reference. The other diseases include pancreatitis, with 4% NaHC03 (1 S mL, X 5). The combined aqueous 
inflammation, and adult respiratory syndrome. Al- washes were acidified to pH 3 using concentrated HCl 
though correlations between in vitro activity of elastase and the resulting precipitate collected. The precipitate 
and chymotrypsin inhibitors and in vivo activity in was dried to give isobutyl 2-carboxyphenyl acetate as a 
animal models have not yet been made for these dis- 55 white solid (1.8 g). The isobutyl 2-carboxyphenyl ace-
eases, it is likely that such correlations will be made tate (0. 7 g) was placed in a mixture of PCls (1.23 g) and 
shortly. And the novel inhibitors can then be used in benzene (20 mL) and the mixture heated at reflux for 30 
any cases where .such correlations are made. min. The solvent was removed and the residue purified 
The following examples are given to illustrate the by silica gel chromatography using benzene as the elu-
invention and are not intended to limit it in any manner. 60 ent to give product as pale yellow needles (338 mg); mp 48; IR (CH2Cl2) 1740 cm-1 Anal. Calcd. for 
C13H13CJ03: C, 61.79; H, 5.19. Found: C, 61.64; H, 5.22. EXAMPLE 1 
Preparation of 3-Benzyloxy-4-Chloroisocoumarin 
Homophthalic acid (0.5 g, 2.78 mmoles) was placed in 
benzyl alcohol (5 mL) and 2 drops of concentrated 65 
sulfuric acid added. The reaction mixture was heated at 
60 to 80 degrees centigrade for 45 min, poured into 50 
mL of ice-cold NaHC03 (4%) and washed with three 
EXAMPLE4 
Preparation of 
7-Nitro-3-Benzyloxy-4-Chloroisocoumarin 
4-Nitro-homophthalic acid (5.0 g) was suspended in 
benzyl alcohol (50 mL) and H2S04(3 drops) added. The 
9 
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reaction mixture was heated at 70-80 degrees centi-
grade for 45 min, diluted into 100 mL of ethyl acetate, 
and washed with 1 L of 4% NaHC03 The aqueous 
layers were combined, acidified to pH 3 using concen-
trated HCl, and extracted with 500 mL of ethyl acetate. 5 
EXAMPLE 7 
Preparation of 
7-(N-Tosyl-Phenylalanylamino)-4-Chloro-3-Methox-
yisocoumarin 
The ethyl acetate layer was dried over magnesium sul- N-Tosyl-phenylalanine acid chloride (77 mg, 0.3 
fate and concentrated to give ca. 4 g of crude product, mmoles) and 7-amino-4-chloro-3-methoxyisocoumarin 
which was titurated with isopropyl ether to give 3.8 (50 mg, 0.2 mmoles) were suspended in a mixture of 
grams of benzyl 2-carboxy-4-nitrophenyl acetate: mp. 10 methylene chloride/tetrahydrofuran (1:1) and triethyl-171-172. Anal. Calcd for C16H13N06: C, 60.96; H, 4.18. amine (0.037 mL, in 2 mL of methylene chloride) added 
Found: C, 60.86; H, 4.18. The benzyl 2-carboxy-4- dropwise with stirring. After stirring at 25° C. for 2 h, 
nitrophenyl acetate (3.0 g) was slowly added to a solu- the reaction solvents were removed and the residue 
tion of PCls (4.35 g) in benzene (150 mL) and the reac- dissolved in ethyl acetate. Atter washing with 10% 
tion·mixture stirred ove·rnight at 25 degrees centigrade. 15 citric acid (3X30 mL) and 4% NaHCQ3 (2X30 mL), 
The benzene solution was washed with 1.2 L of water, the ethyl acetate layer was dried over magnesium sul-
dried over magnesium sulfate and concentrated to give fate and concentrated. The crude product was purified 
a crude yellow solid. The crude product was titurated by silica gel chromatography using a 1 % mixture of 
with isopropyl ether to give 575 mg of a yellow solid methanol in methylene chloride and the 7-(N-tosyl-
. which was purified further by silica gel chromatogra, 20 phenylalanylamino)-4-chloro-3-methoxyisocoumarin 
phy using methylene chloride as the eluent. The pure (22 mg) collected from methanol/isopropyl ether as a 
product was crystallied from methylene chloride to pale yellow solid: mp 222° -224° C. (dee); one spot on 
give 500 mg of yellow needles: mp 153-154 dee, IR TLC, R}=0.3; IR (nujol) 1750 cm-1; mass spectrum 
(CH2Cli) 1785 cm-1, 1622 cm- 1 . Anal. Calcd. for m/e 517 (M+l). Anal. Calcd. for C26H23ClN206S ! 
C16H10ClN05: C, 57.94; H, 3.04; N, 4.22. Found: C, 25 H20: C, 58.26; H, 4.53. Found: C, 58.28; H, 4.50. 
58.04; H, 3.09; N, 4.18. 
EXAMPLE 8 
EXAMPLE 5 
Preparation of 4-Chloro-7-Nitro-3-(2-Phenethoxy) 
isocoumarin 30 
4-Nitrohomophthalic acid (6.0 g, 26.5 mmoles) was 
suspended in 2-phenylethanol (20 mL), H1S04 (3 drops) 
added, and the reaction mixture heated at 120° -130° C. 
for 3.5 h. The mixture was diluted with ethyl acetate 35 (200 mL) and washed with 4% NaHC03 (2 X 300 mL). 
Thin layer chromatography indicated that the product 
was contained primarily in the ethyl acetate layer. After 
concentration of the ethyl acetate layer, the solid was 
titurated with isopropyl ether to give the 2-phenylethyl 40 
ester of 2-carboxy-4-nitrophenylacetic acid (2.0 g) as a 
tan solid and was used without further purification. The 
ester (1.3 g, 3.9 mmoles) was added slowly to a solution 
of PCls (2.05 g, 9.9 mmoles) in benzene (30 mL) and the 
mixture refluxed at 80° C. for 1 h. The benzene was 45 
removed and the residue titurated with petroleum ether. 
The crude product was purified by silica gel chroma-
tography using benzene as the eluent to give 4-chloro-7-
nitro-3(2-phenethoxy) isocoumarin (0.1 g) as an orange 
solid: mp 95°-100° C. (dee), one spot on TLC, R/=05; 50 
IR (nujol) 1752 cm-1. Anal. Calcd. for C11H12CIN05: 
C, 59.05; H, 3.50. Found: C, 58.9; H, 3.55. 
EXAMPLE 6 
Preparation of 
3-Propyl-1 H-2-Benzopyran- l ,4(3H)-dione 
A solution of 3-bromo, 3-(l-bromobutyl)-1(3H)-
isobenzofuranone (500 mg) in Me2SO (15 mL) was 
added dropwise to a solution of O. lM Hepes buffer (pH 
7.5, 50 mL) containing 0.5M NaCl and Me2SO (35 mL). 
The mixture was stirred at 25 degrees centigrade, di-
luted with water (100 mL) and extracted with ethyl 
acetate (50 mL, X 2). The extracts were combined, 
washed with water (50 mL, X 5), dried over magnesium 
sulfate, and concentrated under reduced pressure. The 
residue was chromatographed on silica gel using ben-
zene as the eluent to give the product as a white solid 
(170 mg): mp 44-45 degrees centigrade; IR (nujol), 
1730, 1700 cm-1 Anal. Calcd. for C12H1203: C, 70.57; 
H, 5.92. Found: C, 70.55; H, 5.96. 
Other illustrative examples are given in references 
cited below: 3-chloroisocoumarin: Davies and Poole, J. 
Chem. Soc., pp 1616-1620 (1928); 3,4-
dichloroisocoumarin: Milevskaya, Belinskaya, and 
Yagupol'skil, Zhur, Org. Khim, 9, pp 2145-2149, 
(1973); 3-methoxy-4-chloroisocoumarin and 3-ethoxy-4-
chloroisocoumarin: Tirodkar and Usgaonkar, Ind. J. 
Chem. 7, pp 1114-1116, (1969); 7-nitro-3-methoxy-4-
chloroisocoumarin and 7-amino-3-methoxy-4-
chloroisocoumarin: Choksey and Usgaonkar, Ind. J. 
Preparation of 7-Amino-4-Chloro-3(2-Phenethoxy) 
isocoumarin 
55 Chem. 14B, pp 596-598, (1976). 
The 4-chloro-7-nitro-3-(2-phenethoxy) isocoumarin 
(50 mg, 0.14 mmoles) was dissolved in absolute ethanol 
(50 mL) and hydrogenated using Pd-C (50 mg) for 2 h. 60 
After filtering over celite, the solvent was removed and 
the residue chromatographed on silica gel using methy-
lene chloride as the eluent to give 7-amino-4-chloro-3(2-
phenethoxy) isocoumarin (35 mg) as yellow plates: mp 
105°-107° C.; one spot on TLC, R}=0.45; IR (CH2Cli) 65 
1745 cm-1; mass spectrum m/e 315 (M+ ). Anal. Calcd. 
for C11H14ClN03 C, 64.66; H, 4.47. Found: C, 64.56; H, 
4.51. 
What is claimed is: 
1. A compound of the formula: 
wherein 
0 
R~~ 
~z 
y 
X is selected from the group consisting of 0, and S; 
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Z is selected from the group consisting of H, halogen, 
Cl-C6 alkyl with an attached phenyl, Cl-C6 fluo-
rinated alkyl, Cl-C6 fluorinated alkoxy, Cl-C6 
alkoxy with an attached phenyl, benzyloxy, 4-
fluorobenzyloxy, -OCH2C6H4-R' (2-substitu- 5 
ent); -OCH2C6H4-R' (3-substituent), 
-OCH2C6H4-R' (4-substituent), -OCH2C6-
H3-(R')2 (2,3-substituents), -OCH2C6-
H3-(R')2 (2,4-substituents), -OCH2C6-
H3-(R')2 (2,5-substituents), -OCH2C6~ 10 
H3-(R')2 (2,6-substituents), -OCH2C6-
H3-(R')2 (3,4-substituents), -OCH2C6-
H3-(R')2 (3,5-substituents); 
R' is selected from the group consisting of H, halo-
gen, trifluoromethyl, N02, cyano, methyl, me- 15 
thoxy, acetyl, carboxyl, OH, and amino; 
Y is selected from the group consisting ofH, halogen, 
trifluoromethyl, meth 11. OH, and methoxy, and 
R is selected from the ·group consisting of H, -N-
. H-C(NH-NH2, Cl-C6 fluorinated alkoxy, 20 
Cl-C6 alkyl, and Cl-C6 alkyl amino. 
2. A compound of the formula: 
wherein 
0 
R~~ 
~z 
y 
X is selected from the group consisting of 0, and S; 
25 
30 
Z is selected from the group consisting of H, halogen, 
Cl-C6 alkyl with an attached phenyl, Cl-C6 fluo- 35 
rinated alkyl, Cl-C6 fluorinated alkoxy, Cl-C6 
alkoxy with an attached phenyl, benzyloxy, 4-
fluorobenzyloxy, -OCH2C6H4-R' (2-substitu-
ent), -OCH2C6H4-R' (3-substituent), 
-OCH2C6H4-R' (4-substituent), -OCH2C6-
H3-(R')2 (2,3-substituents), -OCH2C6- 40 
H3-(R')2 (2,4-substituents), -OCH2C6-
H3-(R')2 (2,5-substituents), -OCH2C6-
H3-(R')2 (2,6-substituents), -OCH2C6-
H3-(R')2 (3,4-substituents), -OCH2C6-
H3-(R')2 (3,5-substituents); 45 
R' is selected from the group consisting of H, halo-
gen, trifluoromethyl, N02, cyano, methyl, me-
thoxy, acetyl, carboxyl, OH, and amino; 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH, and methoxy, and SO 
R is selected from the group consisting of OCH3 and 
OH. 
3. A compound of the formula: 
wherein 
0 
R~~ 
~z 
y 
X is selected from the group consisting of 0, and S; 
55 
60 
Z is selected from the group consisting of H, halogen, 65 
Cl-C6 alkyl with an attached phenyl, Cl-C6 fluo-
rinated alkyl, Cl-C6 fluorinated alkoxy, Cl-C6 
alkoxy with an attached phenyl, benzyloxy, 4-
12 
fluorobenzyloxy, -OCH2C6H4-R' (2-substitu-
ent), -OCH2C6H4-R' (3-substituent), 
-OCH2C6H4-R' (4-substituent), -OCH2C6-
H3-(R')2 (2,3-substituents), -OCH2C6-
H3-(R')2 (2,4-substituents), -OCH2C6-
H3-(R')2 (2,5-substituents), -OCH2C6-
H3-(R')2 (2,6-substituents), -OCH2C6-
H3-(R')2 (3,4-substituents), -OCH2C6-
H3-(R')2 (3,5-substituents); 
R' is selected from the group consisting of H, halo-
gen, trifluoromethyl, N02, cyano, methyl, me-
thoxy, acetyl, carboxyl, OH, and amino; 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH, and methoxy, and 
R is selected from the group consisting of NH2 and 
N02. 
4. A compound of the formula: 
wherein 
0 Rwll I x 
:::::::,,.. ~ z 
y 
X is selected from the group consisting of 0, and S; 
Z is halogen; 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH and methoxy, and 
R is selected from the group consisting of OH, NH2, 
N02, halogen, -NH-C(NH)-NH2, 
-C(NH)NH2, Cl-C6 alkoxy, cl-C6 fluorinated 
alkoxy, cl-C6 alkyl, Cl-C6 alkylamino, 
M-AA-NH-, M-AA-0-, M-AA-S-
and M-NH, 
wherein AA is selected from the group consisting 
of alanine, valine, leucine, isoleucine, proline, 
methionine, phenylalanine, tryptophan, glycine, 
serine, threonine, cysteine, tyrosine, asparagine, 
glutamine, aspartic acid, glutamic acid, lysine 
arginine, histidine, beta-alanine, norleucine, nor-
valine, alphaaminobutyric acid, epsilon-
aminocaproic acid, citrulline, hydroxyproline, 
ornithine, and sarcosine, 
wherein M is selected from the group consisting of 
H, lower alkanoyl having 1 to 6 carbons, car-
boxylalkanoyl, hydroxyalkanoyl, amino-alkan-
oyl, benzenesulfonyl, tosyl, benzoyl, and lower 
alkyl sulfonyl having 1 to 6 carbons. 
5. A compound of the formula: 
wherein 
R 1 is selected from the group consisting of halogen, 
Cl-C6 alkyl, Cl-C6 alkyl with an attached phenyl, 
Cl-C6 fluorinated alkyl, Cl-C6 alkoxy, Cl-C6 
fluorinated alkoxy, Cl-C6 alkoxy with an attached 
phenyl, benzyloxy, 4-fluorobenzyloxy, 
13 
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-OCH2C6H4-R' (2-substituent), -OCH2C6H-
4-R' (3-substituent), -OCH2C6H4-R' (4-sub-
stituent), -OCH2C6H3-(R')2 (2,3-substituents), 
-OCH2C6H3-(R')2 (2,4-substituents), 
-OCH2C6H3-(R')2 (2,5-substituents), 5 
-OCH2C6H3-(R')2 (2,6-substituents), 
-OCH2C6H3-(R')2 (3,4-substituents), 
-OCH2C6H3-(R')2 (3,5-substituents); 
R' is selected from the group consisting of H, halo-
10 
15 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
14 
gen, trifluoromethyl, N02, cyano, methyl, me-
thoxy, acetyl, carboxyl, OH, and amino; 
R2 is selected from the group consisting of H, OH, 
NH2, N02, halogen, -NH-C(NH)-NH2, 
-C(NH)NH2, Cl-C6 alkoxy, Cl-C6 fluorinated 
alkoxy, Cl-C6 alkyl, and Cl-C6 alkyl amino. 
* * * * * 
